The DOI matches its Crossref record; 73 of the 79 references it cites were found in a registry or an index.
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Open accessAbstract
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 1 million deaths in the first 6 months of the pandemic and huge economic and social upheaval internationally. An efficacious vaccine is essential to prevent further morbidity and mortality. Although some countries might deploy COVID-19 vaccines on the strength of safety and immunogenicity data alone, the goal of vaccine development is to gain direct evidence of vaccine efficacy in protecting humans against SARS-CoV-2 infection and COVID-19 so that manufacture of efficacious vaccines can be selectively upscaled. A candidate vaccine against SARS-CoV-2 might act against infection, disease, or transmission, and a vaccine capable of reducing any of these elements could contribute to disease control. However, the most important efficacy endpoint, protection against severe disease and death, is difficult to assess in phase 3 clinical trials. In this Review, we explore the challenges in assessing the efficacy of candidate SARS-CoV-2 vaccines, discuss the caveats needed to interpret reported efficacy endpoints, and provide insight into answering the seemingly simple question, "Does this COVID-19 vaccine work?"
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the long-term risks and benefits of a SARS-CoV-2 vaccine will take a long time to fully evaluate in adults33 while the public health needs of a vaccine are pressing.”
From SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges (2021) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Prevalence of Asymptomatic SARS-CoV-2 Infection
Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,348
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility
Arons, M. M., Hatfield, K. M., Reddy, S. C., Kimball, A. A., James, A. E., Jacobs, J. R., Taylor, J., Spicer, K. B., Bardossy, A. C., Oakley, L. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008457 · Cited by 2,051
The COVID-19 vaccine development landscape
Le, T. T., Andreadakis, Z., Kumar, A., Román, R. G., Tollefsen, S., Saville, M. K., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 2,002
Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,960
Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine
Vesikari, T., Matson, D. O., Dennehy, P. H., Damme, P. V., Santosham, M., Rodriguez, Z. M., Dallas, M. J., Heyse, J. F., Goveia, M. G., BLACK, S. B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052664 · Cited by 1,871
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Viral Load Dynamics and Clinical Disease Severity in Patients with SARS-CoV-2 Infection
Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., et al. (2020) · BMJ · doi:10.1136/bmj.m1443 · Cited by 1,479
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Restrepo, A. M. H., Camacho, A., Longini, I. M., Watson, C., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I. D., Doumbia, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,112
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
(2013) · Pluto Press eBooks · doi:10.2307/j.ctt183pb3w.5 · Cited by 908
Vaccines for preventing influenza in healthy adults
Jefferson, T., Pietrantonj, C. D., Rivetti, A., Bawazeer, G. A., Al‐Ansary, L. A., & Ferroni, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001269.pub4 · Cited by 897
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816
Scola, B. L., Bideau, M. L., Andréani, J., Hoang, V. T., Grimaldier, C., Colson, P., Gautret, P., & Raoult, D. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03913-9 · Cited by 812
Vaccines for preventing influenza in the elderly
Demicheli, V., Jefferson, T., Pietrantonj, C. D., Ferroni, E., Thorning, S., Thomas, R. E., & Rivetti, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004876.pub4 · Cited by 712
Interpreting a covid-19 test result
Watson, J., Whiting, P. F., & Brush, J. E. (2020) · BMJ · doi:10.1136/bmj.m1808 · Cited by 712
Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysis
Zhu, J., Ji, P., Pang, J., Zhong, Z., Li, H., He, C., Zhang, J., & Zhao, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25884 · Cited by 637
Geographic and Genomic Distribution of SARS-CoV-2 Mutations
Mercatelli, D., & Giorgi, F. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01800 · Cited by 589
Comparison of seven commercial RT-PCR diagnostic kits for COVID-19
van Kasteren, P. B., van der Veer, B., van den Brink, S., Wijsman, L. A., de Jonge, J., van den Brandt, A., Molenkamp, R., Reusken, C. B. E. M., & Meijer, A. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104412 · Cited by 470
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Whitman, J. D., Hiatt, J. B., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0659-0 · Cited by 455
Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2
Younes, N., Al‐Sadeq, D. W., Al-Jighefee, H. T., Younes, S. N., Al-Jamal, O., Daas, H. I., Yassine, H. M., & Nasrallah, G. K. (2020) · Viruses · doi:10.3390/v12060582 · Cited by 449
Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint
Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Soares‐Weiser, K., MacLehose, H. G., Bergman, H., Ben‐Aharon, I., Nagpal, S., Goldberg, E., Pitan, F., & Cunliffe, N. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008521.pub3 · Cited by 389
Alexandersen, S., Chamings, A., & Bhatta, T. R. (2020) · Nature Communications · doi:10.1038/s41467-020-19883-7 · Cited by 305
Rotavirus vaccines. WHO position paper – January 2013.
Editorial, A. (2013) · PubMed · Cited by 295
Improving recruitment of older people to research through good practice
McMurdo, M. E. T., Roberts, H. C., Parker, S. G., Wyatt, N., May, H. M., Goodman, C. M., Jackson, S., Gladman, J. R. F., O’Mahony, S., Ali, K., et al. (2011) · Age and Ageing · doi:10.1093/ageing/afr115 · Cited by 285
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure
Eyal, N., Lipsitch, M., & Smith, P. G. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa152 · Cited by 283
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19Preprint
Sekine, T., Perez‐Potti, A., Rivera‐Ballesteros, O., Strålin, K., Gorin, J., Olsson, A., Llewellyn‐Lacey, S., Kamal, H., Bogdanović, G., Muschiol, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.174888 · Cited by 272
Test performance evaluation of SARS-CoV-2 serological assaysPreprint
Whitman, J. D., Hiatt, J. B., Mowery, C. T., et al. (2020) · medRxiv · doi:10.1101/2020.04.25.20074856 · Cited by 252
Vaccines for preventing influenza in healthy adults
Demicheli, V., Jefferson, T., Ferroni, E., Rivetti, A., & Pietrantonj, C. D. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001269.pub6 · Cited by 241
Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational Research Roadmap
Weinberg, G. A., & Szilagyi, P. G. (2010) · The Journal of Infectious Diseases · doi:10.1086/652404 · Cited by 230
A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants
Dearlove, B. L., Lewitus, É., Bai, H., Li, Y., Reeves, D. B., Joyce, M. G., Scott, P. T., Amare, M. F., Vasan, S., Michael, N. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008281117 · Cited by 206
Vaccines for preventing influenza in the elderly
Rivetti, D., Jefferson, T., Thomas, R. E., Rudin, M., Rivetti, A., Pietrantonj, C. D., & Demicheli, V. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004876.pub2 · Cited by 206
Zhu, L., Gong, N., Liu, B., Xia, L., Chen, D., Chen, S., Shu, H., Ma, K., Xu, X., Guo, Z., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.039 · Cited by 193
Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
D'Cruz, R. J., Currier, A. W., & Sampson, V. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00468 · Cited by 151
Vaccine effects and impact of vaccination programmes in post-licensure studies
Hanquet, G., Valenciano, M., Simondon, F., & Moren, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.006 · Cited by 144
Wagner, A., & Weinberger, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00717 · Cited by 127
Lambert, P.-H., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.064 · Cited by 119
Self-citationHepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
Ho, J. K., Jeevan-Raj, B. P., & Netter, H. J. (2020) · Viruses · doi:10.3390/v12020126 · Cited by 105
Statistical methodologies to pool across multiple intervention studies
Bangdiwala, S. I., Bhargava, A., O’Connor, D. P., Robinson, T. N., Michie, S., Murray, D. M., Stevens, J., Belle, S. H., Templin, T., & PRATT, C. A. (2016) · Translational Behavioral Medicine · doi:10.1007/s13142-016-0386-8 · Cited by 100
The search for a COVID-19 animal model
Lakdawala, S. S., & Menachery, V. D. (2020) · Science · doi:10.1126/science.abc6141 · Cited by 97
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Soares‐Weiser, K., MacLehose, H. G., Bergman, H., Ben‐Aharon, I., Nagpal, S., Goldberg, E., Pitan, F., & Cunliffe, N. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008521.pub2 · Cited by 90
Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data
Basta, N. E., Halloran, M. E., Matrajt, L., & Longini, I. M. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn259 · Cited by 89
Pooling Data From Individual Clinical Trials in the COVID-19 Era
Petkova, E., Antman, E. M., & Troxel, A. B. (2020) · JAMA · doi:10.1001/jama.2020.13042 · Cited by 83
Recruitment and Retention of Elderly Patients in Clinical Trials: Issues and Strategies
Cassidy, E. L., Baird, E., & Sheikh, J. I. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200105000-00005 · Cited by 82
Velázquez, F. R., Linhares, A. C., Muñoz, S., Pamela Serón, S., Lorca, P., DeAntonio, R., & Ortega‐Barría, E. (2017) · BMC Pediatrics · doi:10.1186/s12887-016-0771-y · Cited by 73
Restricted Social Engagement among Adults Living with Chronic Conditions
Meek, K., Bergeron, C. D., Towne, S. D., Ahn, S., Ory, M. G., & Smith, M. L. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15010158 · Cited by 65
Transmission of SARS-CoV-2, Required Developments in Research and Associated Public Health Concerns
Khan, S., Liu, J., & Xue, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00310 · Cited by 65
Antibody testing will enhance the power and accuracy of COVID-19-prevention trials
Lipsitch, M., Kahn, R. J., & Mina, M. J. (2020) · Nature Medicine · doi:10.1038/s41591-020-0887-3 · Cited by 59
Vekemans, J., Crofts, J., Baker, C. J., Goldblatt, D., Heath, P. T., Madhi, S. A., Doaré, K. L., Andrews, N. J., Pollard, A. J., Saha, S. K., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.039 · Cited by 58
Self-citationColonisation endpoints in Streptococcus pneumoniae vaccine trials
Auranen, K. J., Rinta‐Kokko, H., Goldblatt, D., Nohynek, H., O’Brien, K. L., Satzke, C., Simell, B., Tanskanen, A. J., & Käyhty, H. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.061 · Cited by 57
Herd immunity and vaccination of children for COVID-19
Velavan, T. P., Pollard, A. J., & Kremsner, P. G. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.065 · Cited by 56
Self-citationSensitivity, Specificity, and Vaccine Efficacy
Lachenbruch, P. A. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00042-7 · Cited by 50
Bar‐Zeev, N., King, C., Phiri, T., Beard, J., Mvula, H., Crampin, A. C., Heinsbroek, E., Lewycka, S. O., Tate, J. E., Parashar, U. D., et al. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30314-0 · Cited by 50
Medical Management of COVID-19: Evidence and Experience
Bose, S., Adapa, S., Aeddula, N. R., Roy, S., Nandikanti, D. K., Vupadhyayula, P. M., Naramala, S., Gayam, V. B. R., Muppidi, V., & Konala, V. M. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4201 · Cited by 45
Allsup, S. J., & Gosney, M. (2002) · Gerontology · doi:10.1159/000052837 · Cited by 36
Human challenge models: tools to accelerate the development of malaria vaccines
Cooper, M. M., Loiseau, C., McCarthy, J., & Doolan, D. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1580577 · Cited by 28
Using simulation to aid trial design: Ring-vaccination trials
Hitchings, M. D. T., Grais, R. F., & Lipsitch, M. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005470 · Cited by 28
Baay, M. F. D., & Neels, P. (2020) · Biologicals · doi:10.1016/j.biologicals.2020.08.006 · Cited by 27
Willingness to Participate in Vaccine-Related Clinical Trials among Older Adults
Raheja, D., Davila, E. P., Johnson, E. T., Deović, R., McCullough, M. P., & Rouphael, N. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081743 · Cited by 25
Meiring, J., Giubilini, A., Savulescu, J., Pitzer, V. E., & Pollard, A. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz630 · Cited by 18
Self-citationVaccines for preventing influenza in the elderly
- (2018) · Kazan medical journal · doi:10.17816/kmj8918 · Cited by 10
Research works printed but not linked: 1
- Yu, 2020, DNA vaccine protection against SARS-CoV-2 in rhesus macaques, Science, 369, 806, 10.1126/science.abc6284 · DOI · Paper page
Cited by
Sorted by citations
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Scully, M., Singh, D. N., Lown, R. N., Poles, A., Solomon, T., Levi, M. M., Goldblatt, D., Kotouček, P., Thomas, W. D., & Lester, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105385 · Cited by 964
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Schwarzinger, M., Watson, V., Arwidson, P., Alla, F., & Luchini, S. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00012-8 · Cited by 765
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
Zhang, J., Dong, X., Liu, G., & Gao, Y. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08921-5 · Cited by 782
Metadata
- Authors
- Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Hodgson, Susanne H
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 21
- Issue
- 2
- Pages
- e26-e35
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC7837315
- OpenAlex
- W3088489318
- Cited by
- 633
- References
- 79
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 52 · 2023: 99 · 2022: 221 · 2021: 221
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- UK Research and Innovation (MC_PC_19055)
- Coalition for Epidemic Preparedness Innovations
- National Institute for Health Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, efficacy endpoints, vaccine development
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Clinical Trials as Topic, Humans, Research Design, Vaccination, Treatment Outcome, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
